CareLit Fachartikel
Allogeneic HSCT in patients with MDS
U Platzbecker, A Giagounidis · TumorDiagnostik & Therapie · 2014 · Heft 10
Dokument
1113962
CareLit-ID
Jahr
2014
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Still, allogeneic HSCT remains the only curative option for a small subset of medically fit patients with higher-risk MDS. Patient stratification for allogeneic HSCT is mainly based on MDS risk scores, age and comorbidities. In general, the earlier the transplantation takes place during the disease course the better the chances of long-term cure. On the other hand, patients with less advanced disease should not be exposed to the substantial risk of NRM associated with this procedure. According to a decision model published a decade ago [1] patients with int-2 or high-risk MDS by IPSS criteria should be considere…
Schlagworte
Transplantation
Blood
After
Azacitidine
Diagnosis
Treatment Failure
Biology
TumorDiagnostik & Therapie
